Breaking News: Aeon Biopharma Stays on Track with Development Strategy for ABP-450 Despite Korean Court Ruling on Medytox and Daewoong Pharmaceutical Dispute
AEON Biopharma Responds to Recent Court Ruling IRVINE, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, responded today to the recent ruling by the Seoul Central District Court in…